Stable expression of Shigella sonnei form I O-polysaccharide genes recombineered into the chromosome of live Salmonella oral vaccine vector Ty21a

International Journal of Medical Microbiology

Volumn 303, Issue 3, 2013, Pages 105-113

  Dharmasena, Madushini N ^a   Hanisch, Brock W ^a   Wai, Tint T ^a   Kopecko, Dennis J ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

Bifunctional typhoid shigellosis vaccine; Chromosomal recombineering; Oral vaccine; Shigella sonnei

Indexed keywords

LIPOPOLYSACCHARIDE; O ANTIGEN; TYPHOID VACCINE;

ANIMAL EXPERIMENT; ANTIBIOTIC RESISTANCE; ANTIBODY TITER; ARTICLE; BACTERIAL GENE; BACTERIAL STRAIN; CULTURE MEDIUM; GENE MUTATION; GENETIC CODE; GENETIC RECOMBINATION; GENETIC STABILITY; HETEROLOGOUS EXPRESSION; IMMUNE RESPONSE; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; SHIGELLA DYSENTERIAE; SHIGELLA SONNEI; STABLE EXPRESSION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL VACCINES; BIOSYNTHETIC PATHWAYS; CHROMOSOMES, BACTERIAL; DISEASE MODELS, ANIMAL; DNA, BACTERIAL; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DYSENTERY, BACILLARY; FEMALE; GENOMIC INSTABILITY; MICE; MICE, INBRED BALB C; MOLECULAR BIOLOGY; MOLECULAR SEQUENCE DATA; O ANTIGENS; PLASMIDS; SALMONELLA TYPHI; SEQUENCE ANALYSIS, DNA; SHIGELLA SONNEI; VACCINES, ATTENUATED; VACCINES, SYNTHETIC;

EID: 84875958445     PISSN: 14384221     EISSN: 16180607     Source Type: Journal    
DOI: 10.1016/j.ijmm.2013.01.001     Document Type: Article

References (38)

1. Bardhan P., Faruque A.S., Naheed A., Sack D.A. Decrease in shigellosis-related deaths without Shigella spp.-specific interventions, Asia. Emerg. Infect. Dis. 2010, 16:1718-1723.
2. Black R.E., Levine M.M., Clements M.L., Losonsky G., Herrington D., Berman S., Formal S.B. Prevention of shigellosis by a Salmonella typhi-Shigella sonnei bivalent vaccine. J. Infect. Dis. 1987, 155:1260-1265.
3. Cherepanov P.P., Wackernagel W. Gene disruption in Escherichia coli: TcR and KmR cassettes with the option of Flp-catalyzed excision of the antibiotic-resistance determinant. Gene 1995, 158:9-14.
4. Churchward G., Belin D., Nagamine Y. A pSC101-derived plasmid which shows no sequence homology to other commonly used cloning vectors. Gene 1984, 31:165-171.
5. Crump J.A., Luby S.P., Mintz E.D. The global burden of typhoid fever. Bull. World Health Organ. 2004, 82:346-353.
6. Crump J.A., Mintz E.D. Global trends in typhoid and paratyphoid Fever. Clin. Infect. Dis. 2010, 50:241-246.
7. D'Amelio R., Tagliabue A., Nencioni L., Di Addario A., Villa L., Manganaro M., Boraschi D., Le Moli S., Nisini R., Matricardi P.M. Comparative analysis of immunological responses to oral (Ty21a) and parenteral (TAB) typhoid vaccines. Infect. Immun. 1988, 56:2731-2735.
8. Datsenko K.A., Wanner B.L. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:6640-6645.
9. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., Gangarosa E.J. Immunity in shigellosis. I. Response of man to attenuated strains of Shigella. J. Infect. Dis. 1972, 125:5-11.
10. DuPont H.L., Hornick R.B., Snyder M.J., Libonati J.P., Formal S.B., Gangarosa E.J. Immunity in shigellosis II. Protection induced by oral live vaccine or primary infection. J. Infect. Dis. 1972, 125:12-16.
11. Ferreccio C., Prado V., Ojeda A., Cayyazo M., Abrego P., Guers L., Levine M.M. Epidemiologic patterns of acute diarrhea and endemic Shigella infections in children in a poor periurban setting in Santiago, Chile. Am. J. Epidemiol. 1991, 134:614-627.
12. Formal S.B., Baron L.S., Kopecko D.J., Washington O., Powell C., Life C.A. Construction of a potential bivalent vaccine strain: introduction of Shigella sonnei form I antigen genes into the galE Salmonella typhi Ty21a typhoid vaccine strain. Infect. Immun. 1981, 34:746-750.
13. Germanier R., Furer E. Isolation and characterization of Gal E mutant Ty 21a of Salmonella typhi: a candidate strain for a live, oral typhoid vaccine. J. Infect. Dis. 1975, 131:553-558.
14. Herrington D.A., Van de Verg L., Formal S.B., Hale T.L., Tall B.D., Cryz S.J., Tramont E.C., Levine M.M. Studies in volunteers to evaluate candidate Shigella vaccines: further experience with a bivalent Salmonella typhi-Shigella sonnei vaccine and protection conferred by previous Shigella sonnei disease. Vaccine 1990, 8:353-357.
15. Kaminski R.W., Oaks E.V. Inactivated and subunit vaccines to prevent shigellosis. Expert Rev. Vaccines 2009, 8:1693-1704.
16. Kopecko D.J., Washington O., Formal S.B. Genetic and physical evidence for plasmid control of Shigella sonnei form I cell surface antigen. Infect. Immun. 1980, 29:207-214.
17. Kopecko D.J., Sieber H., Ures J.A., Furer A., Schlup J., Knof U., Collioud A., Xu D., Colburn K., Dietrich G. Genetic stability of vaccine strain Salmonella Typhi Ty21a over 25 years. Int. J. Med. Microbiol. 2009, 299:233-246.
18. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999, 17(Suppl. 2):S22-S27.
19. Levine M.M., Ferreccio C., Black R.E., Lagos R., San Martin O., Blackwelder W.C. Ty21a live oral typhoid vaccine and prevention of paratyphoid fever caused by Salmonella enterica Serovar Paratyphi B. Clin. Infect. Dis. 2007, 45(Suppl. 1):S24-S28.
20. Marathe S.A., Lahiri A., Negi V.D., Chakravortty D. Typhoid fever & vaccine development: a partially answered question. Indian J. Med. Res. 2012, 135:161-169.
21. Mead P.S., Slutsker L., Dietz V., McCaig L.F., Bresee J.S., Shapiro C., Griffin P.M., Tauxe R.V. Food-related illness and death in the United States. Emerg. Infect. Dis. 1999, 5:607-625.
22. Murphy K.C. Use of bacteriophage lambda recombination functions to promote gene replacement in Escherichia coli. J. Bacteriol. 1998, 180:2063-2071.
23. Nisini R., Biselli R., Matricardi P.M., Fattorossi A., D'Amelio R. Clinical and immunological response to typhoid vaccination with parenteral or oral vaccines in two groups of 30 recruits. Vaccine 1993, 11:582-586.
24. Noriega F.R., Liao F.M., Maneval D.R., Ren S., Formal S.B., Levine M.M. Strategy for cross-protection among Shigella flexneri serotypes. Infect. Immun. 1999, 67:782-788.
25. Ohtake S., Martin R., Saxena A., Pham B., Chiueh G., Osorio M., Kopecko D., Xu D., Lechuga-Ballesteros D., Truong-Le V. Room temperature stabilization of oral, live attenuated Salmonella enterica serovar Typhi-vectored vaccines. Vaccine 2011, 29:2761-2771.
26. Osorio M., Wu Y., Singh S., Merkel T.J., Bhattacharyya S., Blake M.S., Kopecko D.J. Anthrax protective antigen delivered by Salmonella enterica serovar Typhi Ty21a protects mice from a lethal anthrax spore challenge. Infect. Immun. 2009, 77:1475-1482.
27. Pickett T.E., Pasetti M.F., Galen J.E., Sztein M.B., Levine M.M. In vivo characterization of the murine intranasal model for assessing the immunogenicity of attenuated Salmonella enterica serovar Typhi strains as live mucosal vaccines and as live vectors. Infect. Immun. 2000, 68:205-213.
28. Putthasri W., Lertiendumrong J., Chompook P., Tangcharoensathien V., Coker R. Capacity of Thailand to contain an emerging influenza pandemic. Emerg. Infect. Dis. 2009, 15:423-432.
29. Sawitzke J.A., Thomason L.C., Costantino N., Bubunenko M., Datta S., Court D.L. Recombineering: in vivo genetic engineering in E. coli, S. enterica, and beyond. Methods Enzymol. 2007, 421:171-199.
30. Schwartz E., Shlim D.R., Eaton M., Jenks N., Houston R. The effect of oral and parenteral typhoid vaccination on the rate of infection with Salmonella typhi and Salmonella paratyphi A among foreigners in Nepal. Arch. Intern. Med. 1990, 150:349-351.
31. Seid R.C., Kopecko D.J., Sadoff J.C., Schneider H., Baron L.S., Formal S.B. Unusual lipopolysaccharide antigens of a Salmonella typhi oral vaccine strain expressing the Shigella sonnei form I antigen. J. Biol. Chem. 1984, 259:9028-9034.
32. Uzzau S., Figueroa-Bossi N., Rubino S., Bossi L. Epitope tagging of chromosomal genes in Salmonella. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:15264-15269.
33. Van de Verg L., Herrington D.A., Murphy J.R., Wasserman S.S., Formal S.B., Levine M.M. Specific immunoglobulin A-secreting cells in peripheral blood of humans following oral immunization with a bivalent Salmonella typhi-Shigella sonnei vaccine or infection by pathogenic S. sonnei. Infect. Immun. 1990, 58:2002-2004.
34. Wahid R., Simon R., Zafar S.J., Levine M.M., Sztein M.B. Live Oral Typhoid Vaccine Ty21a Induces Cross-Reactive Humoral Immune Responses against Salmonella enterica Serovar Paratyphi A and S. Paratyphi B in Humans. Clin. Vaccine Immunol. 2012, 19:825-834.
35. WHO Guidelines for the Control of Shigellosis, including Epidemics due to Shigella dysenteriae Type 1 2005, World Health Organization, Geneva Switzerland.
36. Xu D.Q., Cisar J.O., Ambulos N., Burr D.H., Kopecko D.J. Molecular cloning and characterization of genes for Shigella sonnei form I O polysaccharide: proposed biosynthetic pathway and stable expression in a live salmonella vaccine vector. Infect. Immun. 2002, 70:4414-4423.
37. Xu D.Q., Cisar J.O., Osorio M., Wai T.T., Kopecko D.J. Core-linked LPS expression of Shigella dysenteriae serotype 1 O-antigen in live Salmonella Typhi vaccine vector Ty21a: preclinical evidence of immunogenicity and protection. Vaccine 2007, 25:6167-6175.
38. Yu B., Yang M., Wong H.Y., Watt R.M., Song E., Zheng B.J., Yuen K.Y., Huang J.D. A method to generate recombinant Salmonella typhi Ty21a strains expressing multiple heterologous genes using an improved recombineering strategy. Appl. Microbiol. Biotechnol. 2011, 91:177-188.